Literature DB >> 16385559

A folding inhibitor of the HIV-1 protease.

R A Broglia1, D Provasi, F Vasile, G Ottolina, R Longhi, G Tiana.   

Abstract

Because the human immunodeficiency virus type 1 protease (HIV-1-PR) is an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single-domain proteins, like each of the monomers forming the HIV-1-PR homodimer, is controlled by local elementary structures (LES, folding units stabilized by strongly interacting, highly conserved, as a rule hydrophobic, amino acids). These LES have evolved over myriad generations to recognize and strongly attract each other, so as to make the protein fold fast and be stable in its native conformation. Consequently, peptides displaying a sequence identical to those segments of the monomers associated with LES are expected to act as competitive inhibitors and thus destabilize the native structure of the enzyme. These inhibitors are unlikely to lead to escape mutants as they bind to the protease monomers through highly conserved amino acids, which play an essential role in the folding process. The properties of one of the most promising inhibitors of the folding of the HIV-1-PR monomers found among these peptides are demonstrated with the help of spectrophotometric assays and circular dichroism spectroscopy. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16385559     DOI: 10.1002/prot.20849

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  12 in total

1.  Identification of the folding inhibitors of hen-egg lysozyme: gathering the right tools.

Authors:  Martina Caldarini; Ludovico Sutto; Carlo Camilloni; Francesca Vasile; Ricardo A Broglia; Guido Tiana
Journal:  Eur Biophys J       Date:  2009-03-27       Impact factor: 1.733

2.  Atomistic simulations of the HIV-1 protease folding inhibition.

Authors:  Gennady Verkhivker; Guido Tiana; Carlo Camilloni; Davide Provasi; Ricardo A Broglia
Journal:  Biophys J       Date:  2008-03-28       Impact factor: 4.033

3.  Thermodynamics of strongly allosteric inhibition: a model study of HIV-1 protease.

Authors:  S Kimura; R A Broglia; G Tiana
Journal:  Eur Biophys J       Date:  2012-10-05       Impact factor: 1.733

4.  Insight into the folding inhibition of the HIV-1 protease by a small peptide.

Authors:  Massimiliano Bonomi; Francesco L Gervasio; Guido Tiana; Davide Provasi; Ricardo A Broglia; Michele Parrinello
Journal:  Biophys J       Date:  2007-06-15       Impact factor: 4.033

5.  Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

Authors:  David A Davis; Irene R Tebbs; Sarah I Daniels; Stephen J Stahl; Joshua D Kaufman; Paul Wingfield; Michael J Bowman; Jean Chmielewski; Robert Yarchoan
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

6.  Multiple routes and milestones in the folding of HIV-1 protease monomer.

Authors:  Massimiliano Bonomi; Alessandro Barducci; Francesco L Gervasio; Michele Parrinello
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

7.  Optimizing HIV-1 protease production in Escherichia coli as fusion protein.

Authors:  Federica Volontè; Luciano Piubelli; Loredano Pollegioni
Journal:  Microb Cell Fact       Date:  2011-06-30       Impact factor: 5.328

8.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20

9.  Synthesis and Inhibiting Activity of Some 4-Hydroxycoumarin Derivatives on HIV-1 Protease.

Authors:  Stancho Stanchev; Frank Jensen; Anton Hinkov; Vasil Atanasov; Petia Genova-Kalou; Radka Argirova; Ilia Manolov
Journal:  ISRN Pharm       Date:  2011-07-26

Review 10.  Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Authors:  Iakov N Rudenko; Ruth Chia; Mark R Cookson
Journal:  BMC Med       Date:  2012-02-23       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.